ReviewCurrent pharmaceutical design2025
A Mini-Review on the Symptoms and Pathogenesis of Psoriasis and Recent Nanotechnological Developments in its Treatment Strategies.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Psoriasis is a chronic disease that is common and incurable. In psoriasis, skin cells proliferate more quickly than normal cells, suggesting a possible immune system connection. The topical treatment of psoriasis is best when applied in combination with anti-inflammatory medications; however, the lack of an appropriate delivery method limits the drugs' ability to be delivered. Due to several problems, including adverse reactions and problems with penetration, the current oral and topical treatments for psoriasis fall short of meeting the need for an optimal drug delivery method. None of them, however, can completely treat the illness safely and effectively without jeopardizing patient adherence. ILC3 typically contains retinoic acid receptor-related orphan receptor gamma t (RORγt) in its nucleus. Its development occurs when stimulated by IL-23 and IL-7, leading to the production of IL-22 and IL-17. Both the innate and adaptive immune systems are implicated in the recent, substantial advancements in genetics and molecular biology that have improved our understanding of PsA pathogenesis. Evidence-based targeted therapy has been introduced as a result, mostly using drugs known as tumour necrosis factor inhibitors. Because of their high ethanol concentration, etheromethanes provide more effective and improved bioavailability compared to previous dosing formulations. The principles, preparation process, most recent developments, and applications of ethosomes, however, are not well described in a systematic study. Size, shape, drug content, zeta potential, and other characteristics are examples of ethosome characteristics. Esthosomes can be prepared using four distinct methods, including thin-film hydration, the cold method, the hot method, and the reverse-phase evaporation method. All the information presented in this article was gathered from diverse sources, such as PubMed, ScienceDirect, Google Scholar, and various online platforms, like WHO, Globacon, and others.
Indexed as
Identifiers
40148295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.